Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer (Q41722410)

8 October 2017

title

Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer (English)

1 reference

8 October 2017

Xi Gu

1

1 reference

8 October 2017

Yang Zhang

2

1 reference

8 October 2017

Long Chen

3

1 reference

8 October 2017

Jiao Guo

4

1 reference

8 October 2017

Wen-Hai Zhang

5

1 reference

8 October 2017

publication date

6 December 2014

1 reference

Cancer Chemotherapy and Pharmacology

8 October 2017

published in

1 reference

8 October 2017

volume

75

1 reference

8 October 2017

issue

2

1 reference

8 October 2017

page(s)

301-308

1 reference

Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

MRgFUS: from diagnosis to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Genomic index of sensitivity to endocrine therapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Emerging targeted therapies for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Proliferation determined by ki67 marker and pCR in locally advanced breast cancer patients treated with neo-adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Revision of the American Joint Committee on Cancer staging system for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor res

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

A gene expression profile indicative of early stage HER2 targeted therapy response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Neoadjuvant treatments for triple-negative breast cancer (TNBC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2646-Y

10.1007/S00280-014-2646-Y

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

8 October 2017

1032318205

0 references

1 reference